Immunotherapies have revolutionized cancer treatment over the last 20 years. They aim
either to boost immune cell activation or decrease immune cell inhibition, to improve control …

Although the first cancer immunotherapy was given in the clinic more than a century ago,
this line of treatment has remained more of a distant goal than a practical therapy due to …

Immunotherapies targeting conventional T cells have revolutionized systemic treatment for
many cancers, yet only a subset of patients benefit from these approaches. A better …

The development of immunotherapies represents a major advance towards the effective
eradication of malignant tumors. So far, therapeutic approaches have largely focused on T …

Innate lymphoid cells (ILCs) were found to be developmentally related to natural killer (NK)
cells. In humans, they are mostly located in “barrier” tissues where they contribute to innate …

The recognition of the important role of cancer immunity in tumors has led to the introduction
of immunotherapeutic strategies. Most of the immunomodulatory approaches currently being …

Innate lymphoid cells (ILCs) are the most recently characterized subset of innate
lymphocytes. Based on their specific transcriptional regulation, cytokine secretion pattern …

In recent years, immunotherapy has become the most promising therapy for a variety of
cancer types. The development of immune checkpoint blockade (ICB) therapies, the …

Cancer immunotherapy has led to impressive advances in cancer treatment. Unfortunately,
in a high percentage of patients is difficult to consistently restore immune responses to …

Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …